404 related articles for article (PubMed ID: 26359458)
21. MAGE-A Cancer/Testis Antigens Inhibit MDM2 Ubiquitylation Function and Promote Increased Levels of MDM4.
Marcar L; Ihrig B; Hourihan J; Bray SE; Quinlan PR; Jordan LB; Thompson AM; Hupp TR; Meek DW
PLoS One; 2015; 10(5):e0127713. PubMed ID: 26001071
[TBL] [Abstract][Full Text] [Related]
22. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
23. The fluorescent two-hybrid assay to screen for protein-protein interaction inhibitors in live cells: targeting the interaction of p53 with Mdm2 and Mdm4.
Yurlova L; Derks M; Buchfellner A; Hickson I; Janssen M; Morrison D; Stansfield I; Brown CJ; Ghadessy FJ; Lane DP; Rothbauer U; Zolghadr K; Krausz E
J Biomol Screen; 2014 Apr; 19(4):516-25. PubMed ID: 24476585
[TBL] [Abstract][Full Text] [Related]
24. The MDM4/MDM2-p53-IGF1 axis controls axonal regeneration, sprouting and functional recovery after CNS injury.
Joshi Y; Sória MG; Quadrato G; Inak G; Zhou L; Hervera A; Rathore KI; Elnaggar M; Cucchiarini M; Marine JC; Puttagunta R; Di Giovanni S
Brain; 2015 Jul; 138(Pt 7):1843-62. PubMed ID: 25981963
[TBL] [Abstract][Full Text] [Related]
25. Discovery of MDM2-p53 and MDM4-p53 protein-protein interactions small molecule dual inhibitors.
Espadinha M; Lopes EA; Marques V; Amaral JD; Dos Santos DJVA; Mori M; Daniele S; Piccarducci R; Zappelli E; Martini C; Rodrigues CMP; Santos MMM
Eur J Med Chem; 2022 Nov; 241():114637. PubMed ID: 35961068
[TBL] [Abstract][Full Text] [Related]
26. Synergistic roles of Mdm2 and Mdm4 for p53 inhibition in central nervous system development.
Xiong S; Van Pelt CS; Elizondo-Fraire AC; Liu G; Lozano G
Proc Natl Acad Sci U S A; 2006 Feb; 103(9):3226-31. PubMed ID: 16492743
[TBL] [Abstract][Full Text] [Related]
27. The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers.
Abdel-Fatah TM; Powe DG; Agboola J; Adamowicz-Brice M; Blamey RW; Lopez-Garcia MA; Green AR; Reis-Filho JS; Ellis IO
J Pathol; 2010 Mar; 220(4):419-34. PubMed ID: 20044801
[TBL] [Abstract][Full Text] [Related]
28. Mdm2 and Mdm4 loss regulates distinct p53 activities.
Barboza JA; Iwakuma T; Terzian T; El-Naggar AK; Lozano G
Mol Cancer Res; 2008 Jun; 6(6):947-54. PubMed ID: 18567799
[TBL] [Abstract][Full Text] [Related]
29. The p53-Mdm2 interaction and the E3 ligase activity of Mdm2/Mdm4 are conserved from lampreys to humans.
Coffill CR; Lee AP; Siau JW; Chee SM; Joseph TL; Tan YS; Madhumalar A; Tay BH; Brenner S; Verma CS; Ghadessy FJ; Venkatesh B; Lane DP
Genes Dev; 2016 Feb; 30(3):281-92. PubMed ID: 26798135
[TBL] [Abstract][Full Text] [Related]
30. Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice.
Iwakuma T; Parant JM; Fasulo M; Zwart E; Jacks T; de Vries A; Lozano G
Oncogene; 2004 Oct; 23(46):7644-50. PubMed ID: 15361844
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of the p53-MDM2 interaction: targeting a protein-protein interface.
Chène P
Mol Cancer Res; 2004 Jan; 2(1):20-8. PubMed ID: 14757842
[TBL] [Abstract][Full Text] [Related]
32. Mdmx enhances p53 ubiquitination by altering the substrate preference of the Mdm2 ubiquitin ligase.
Okamoto K; Taya Y; Nakagama H
FEBS Lett; 2009 Sep; 583(17):2710-4. PubMed ID: 19619542
[TBL] [Abstract][Full Text] [Related]
33. E2F-1 transcriptional activity is a critical determinant of Mdm2 antagonist-induced apoptosis in human tumor cell lines.
Kitagawa M; Aonuma M; Lee SH; Fukutake S; McCormick F
Oncogene; 2008 Sep; 27(40):5303-14. PubMed ID: 18521084
[TBL] [Abstract][Full Text] [Related]
34. Targeting RING domains of Mdm2-MdmX E3 complex activates apoptotic arm of the p53 pathway in leukemia/lymphoma cells.
Wu W; Xu C; Ling X; Fan C; Buckley BP; Chernov MV; Ellis L; Li F; Muñoz IG; Wang X
Cell Death Dis; 2015 Dec; 6(12):e2035. PubMed ID: 26720344
[TBL] [Abstract][Full Text] [Related]
35. MDM2 and MDM4 Are Therapeutic Vulnerabilities in Malignant Rhabdoid Tumors.
Howard TP; Arnoff TE; Song MR; Giacomelli AO; Wang X; Hong AL; Dharia NV; Wang S; Vazquez F; Pham MT; Morgan AM; Wachter F; Bird GH; Kugener G; Oberlick EM; Rees MG; Tiv HL; Hwang JH; Walsh KH; Cook A; Krill-Burger JM; Tsherniak A; Gokhale PC; Park PJ; Stegmaier K; Walensky LD; Hahn WC; Roberts CWM
Cancer Res; 2019 May; 79(9):2404-2414. PubMed ID: 30755442
[TBL] [Abstract][Full Text] [Related]
36. Heterodimerization of Mdm2 and Mdm4 is critical for regulating p53 activity during embryogenesis but dispensable for p53 and Mdm2 stability.
Pant V; Xiong S; Iwakuma T; Quintás-Cardama A; Lozano G
Proc Natl Acad Sci U S A; 2011 Jul; 108(29):11995-2000. PubMed ID: 21730132
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathways: targeting Mdm2 and Mdm4 in cancer therapy.
Li Q; Lozano G
Clin Cancer Res; 2013 Jan; 19(1):34-41. PubMed ID: 23262034
[TBL] [Abstract][Full Text] [Related]
38. Stapled peptides with improved potency and specificity that activate p53.
Brown CJ; Quah ST; Jong J; Goh AM; Chiam PC; Khoo KH; Choong ML; Lee MA; Yurlova L; Zolghadr K; Joseph TL; Verma CS; Lane DP
ACS Chem Biol; 2013 Mar; 8(3):506-12. PubMed ID: 23214419
[TBL] [Abstract][Full Text] [Related]
39. Downregulation of Mdm2 and Mdm4 enhances viral gene expression during adenovirus infection.
Yang H; Zheng Z; Zhao LY; Li Q; Liao D
Cell Cycle; 2012 Feb; 11(3):582-93. PubMed ID: 22262167
[TBL] [Abstract][Full Text] [Related]
40. Regulating the p53 pathway: in vitro hypotheses, in vivo veritas.
Toledo F; Wahl GM
Nat Rev Cancer; 2006 Dec; 6(12):909-23. PubMed ID: 17128209
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
